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Abstract
Background: Participant non-adherence and loss to follow-up can compromise the validity of clinical trial results. An
assessment of these issues was made in a 3-year tuberculosis prevention trial among HIV-infected adults in Botswana.
Methods and Findings: Between 11/2004–07/2006, 1995 participants were enrolled at eight public health clinics. They
returned monthly to receive bottles of medication and were expected to take daily tablets of isoniazid or placebo for three
years. Non-adherence was defined as refusing tablet ingestion but agreeing to quarterly physical examinations. Loss to
follow-up was defined as not having returned for appointments in $60 days. Between 10/2008–04/2009, survey interviews
were conducted with 83 participants identified as lost to follow-up and 127 identified as non-adherent. As a comparison,
252 randomly selected adherent participants were also surveyed. Multivariate logistic regression analysis was used to
identify associations with selected risk factors. Men had higher odds of being non-adherent (adjusted odds ratio (AOR), 2.24;
95% confidence interval [95%CI] 1.24–4.04) and lost to follow-up (AOR 3.08; 95%CI 1.50–6.33). Non-adherent participants
had higher odds of reporting difficulties taking the regimen or not knowing if they had difficulties (AOR 3.40; 95%CI 1.75–
6.60) and lower odds associated with each year of age (AOR 0.95; 95%CI 0.91–0.98), but other variables such as employment,
distance from clinic, alcohol use, and understanding study requirements were not significantly different than controls.
Among participants who were non-adherent or lost to follow-up, 40/210 (19.0%) reported that they stopped the medication
because of work commitments and 33/210 (15.7%) said they thought they had completed the study.
Conclusions: Men had higher odds of non-adherence and loss to follow-up than women. Potential interventions that might
improve adherence in trial participants may include:targeting health education for men, reducing barriers, clarifying study
expectations, educating employers about HIV/AIDS to help reduce stigma in the workplace, and encouraging employers to
support employee health.
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Introduction
Non-adherence and loss to follow-up in a clinical trial threatens
the validity of conclusions about the intervention. The Botswana
Isoniazid Preventive Therapy (IPT) clinical trial was conducted
between November 2004 and July 2009. It was a double-blinded,
randomized, placebo-controlled clinical trial to determine whether
isoniazid taken daily for 36 months was more effective in
protecting against tuberculosis (TB) in HIV-infected adults
compared to the standard-of-care in which isoniazid was taken
daily for six months. The researchers reported that participants
receiving 36 months of IPT had half the risk of TB compared to
participants receiving the 6-month regimen [1]. During the
conduct of the trial, a sub-study was conducted to assess the
causes of non-adherence.
While IPT reduces the incidence of TB disease among HIV and
TB co-infected individuals [2], adherence may be difficult because
of the long duration of prophylaxis. Typically, patients with
chronic conditions have poorer medication adherence than those
with acute conditions [3]. It is important to understand factors
associated with non-adherence so that high adherence can be
maintained or low adherence improved [3–6] since adherence to
effective treatment improves health outcomes [7,8].
Non-adherence to medication regimens is observed in clinical
trials and is common under routine program conditions.
Participants may wish to stop taking the medication or cease
returning for clinic appointments. In order to better understand
what factors affected non-adherence in our study, we conducted a
sub-study in which we identified two distinct groups of non-
adherent participants:participants who refused to take the study
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who were lost to follow-up. Demographic characteristics and other
risk factors of these two groups were compared against those who
remained adherent in the Botswana IPT clinical trial. As an earlier
analysis of trial data found that being on antiretroviral therapy
(ART) was associated with better IPT adherence [9], we included
ART use as a risk factor.
Methods
Study population
Potential participants for the clinical trial were recruited from 5
public health clinics in Gaborone and 3 in Francistown [1,9].
Participants in the trial were $18 years of age and infected with
HIV and all were required to pass a 20-question study
comprehension quiz before enrollment. Subsequent to enrolment
in the trial, ART was provided to eligible study participants
through routine government services for management of their
HIV infection. Participants were required to take isoniazid or
placebo and one tablet of vitamin B6 daily for three years. Those
who also initiated ART typically took 2 pills twice daily in addition
to the study medications. Study nurses provided bottles of study
medication and interviewed participants monthly, provided
reminder cards for their visits and performed pill counts with
the participants on a quarterly basis. The expected visit window
for the monthly pharmacy refill was 7 days early or 14 days late in
the 30-day study month. The visit window was included to allow
some flexibility to the study participants and the time frame chosen
was based upon practical considerations specific to the study area.
If a study participant did not attend a visit, nurses and retention
officers attempted to reach her/him, her/his designated friend or
family member by mobile phone at first and subsequently paid
visits to her/his home. Participants stopping study medication
because of adverse events or refusal to continue taking their pills
were invited to remain in the study and were followed off study
medication for the remainder of the trial.
Participants in the current sub-study were divided into cases
and controls (Fig. 1). Information about frequency of returns for
scheduled medication pick-up visits (pharmacy refill) was used to
identify controls and two types of cases. The types of cases were
those who continued attending clinic visits but were non-adherent
(case non-adherent) and those lost to follow-up (case lost to
follow-up). Non-adherence was defined as 1) refusal to take any
more study medication, 2) agreeing to attend quarterly visits and
3) seen at the last expected visit. Loss to follow-up was defined as
1) a participant who was still expected to take the study
medication and receive monthly medication refills and 2) missed
the last visit by $60 days. A control was defined as 1) a
participant who continued to be on study medication and 2) last
seen within the expected visit window. Participants who
completed the first 6 months of daily isoniazid and subsequently
missed study medications or scheduled visits were invited to
resume taking their medication and were considered adherent for
the sub-study if they agreed to and returned sooner than 60 days.
Between 10/2008–04/2009, 102 participants were identified as
lost to follow-up, 145 were identified as non-adherent. As a
comparison an equal number of controls were randomly selected
from 1370 adherent participants. Random selection is superior to
other methods of sampling [10,11]. Participants who developed
severe adverse events, TB disease or died were excluded from
consideration as either cases or controls. According to the study
protocol, research staff were not permitted to contact participants
who had voluntarily withdrawn.
Procedures
Rates of pharmacy refill visits among enrolled participants were
determined using a criterion of attending $80% of visits within six
6-month periods (Table 1). As part of the main IPT trial, without
prior notification, urine samples were collected from 200
randomly selected participants in the 36-months and 50
participants in the placebo arm who continued to return to the
clinic by study nurses and analyzed by non-study staff for isoniazid
metabolites [12] on three occasions approximately one year apart.
Results of isoniazid metabolite testing were reported in aggregate
by the study statistician so that double-blinding was maintained.
In order to better understand factors associated with non-
adherence and loss to follow-up, a third party (a private company
in Botswana) was hired to contact sub-study participants and carry
out the focus group discussions, interviews and surveys. This third
party was enlisted in order to reduce the risk that study
participants would be less than forthcoming in their responses to
questions and also to facilitate finding lost to follow-up
Figure 1. Derivation of cases and controls for the adherence
sub-study from the cohort of HIV-infected persons enrolled in
the Botswana Isoniazid Preventive Therapy Trial, 2004–2008.
Case-Non-adherent was defined as not taking the study medication due
to unwillingness to take any more study medication but continuing to
attend quarterly visits and seen at the last expected visit. Case-LosT to
follow-up was defined as a participant who was still expected to take
the study medication and receive monthly medication refills but missed
the last visit by$60 days. A control was defined as a participant who
continued to be on study medication and was last seen within the
expected visit window which was 7 days early or 14 days late in the 30-
day study month. The median number of days since the last visit of
those cases who were lost to follow-up was 396 days (range 91–1196),
and 48 days (range 6–116) for the cases who were non-adherent. As the
sub-study was conducted between 10/2008 AND 4/2009, 21 PARTIC-
IPANTS HAS ALREADY COMPLETED THE RQUIRED 36 MONTHS OF
OBSERVATION AND HAD VOLUNTARILY WITHDRAWN.
doi:10.1371/journal.pone.0018435.g001
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were first conducted to provide supplemental information and to
help finalize a survey that was administered during the second
phase of the study (the complete questionnaire is available upon
request). Native Setswana-speaking persons moderated the focus
group discussions and interviews.
Phase 1: Group discussions and individual interviews. Group
and individual interviews were conducted prior to finalizing the survey
instrument to assure that relevant questions were included. Purposeful
sampling, or selecting participants based on their ability to provide
information on the relevant subject [13], was used to choose 42
participants using the criterion that they could be categorized as a case
non-adherent or a case lost to follow-up as defined above. Groups were
divided by sex to ensure that the females would have a chance to express
themselves freely due to the sensitiv en a t u r eo ft h et o p i c .T h e r ew e r e3
groups of women and 2 groups of men. A semi-structured focus group
moderator and individual interview guide was prepared to elicit
information about participants’ thoughts and opinions about the trial
as well as reasons for non-adherence. The guide queried reasons for
joining the trial, knowledge of TB, why isoniazid prophylaxis is important
for persons infected with HIV, barriers to trial participation, adequacy of
information provided about the trial, perception of the care and
treatment provided by trial staff, benefits of being in the trial, and reasons
participants stopped taking the study pills.
Phase 2: Survey. The survey instrument was interviewer-
administered and consisted primarily of close-ended questions.
Participants (247 cases and 253 controls, see Fig. 1) were contacted
by phone to set up a time to have the survey administered at an
office in Gaborone or Francistown and were given the option to
have the survey administered over the phone. Focus group and
individual interview participants were not excluded from
participating in the survey. Reimbursements were deposited to
the participants’ bank accounts or given directly to those who
came to the offices. Survey items covered the same topics as the
moderator’s guide.
Ethics Statement
Participants were provided explanations about the sub-study,
were told that the information they provided would be
confidential, and were informed that their participation was
voluntary so they could refuse to answer any questions or leave the
focus group at any time. Verbal, not written, consent was obtained
for this sub-study because the risks were minimal and participants
had already provided written consent for the parent clinical trial.
The ethics committees agreed that verbal consent was sufficient.
For the survey and interviews, if the potential participant refused
to participate and consent, this was recorded. All participants
designated as cases who participated in the group discussion or
individual interviews received a monetary reimbursement (ap-
proximately U.S. $8.00) for their time and transportation costs.
Ethical approval was obtained from the Botswana Ministry of
Health’s Human Research Development Committee and the
Centers for Disease Control and Prevention’s Institutional Review
Board (see Protocol S1 and Checklist S1). The clinical trial is
registered at clinicaltrials.gov, NCT00164281.
Analysis
Qualitative Analysis. Nvivo, a qualitative data analysis
program, was used to organize the data and code themes from
transcribed discussions and interviews. A ‘‘grounded theory’’
method was used for data analysis, an inductive approach where
theory is generated from the data. Two researchers independently
read and coded two of the 12 transcripts in order to assess inter-
coder reliability. The researchers read and discussed their coding
to reach consensus. Cohen’s kappa coefficient for 22 questions in
these transcripts prior to their resolutions ranged from 0.82 to
0.93. One researcher (DG) performed the final coding of all
discussions and interviews. Quotes were selected on the basis of
their clear representation of the key themes.
Quantitative Analysis. We conducted bivariate and multiple
regression analyses to test for differences in several variables of
interest between controls and cases. For bivariate analyses, chi-
square tests were used and, in the case of the continuous variable,
age, a t-test was used. For multiple regression analyses, two logistic
regression models were constructed; one model assessed differ-
ences between controls and non-adherent cases and the second
model assessed differences between controls and cases lost to
follow-up. All of the independent variables with a P-value ,0.25 in
bivariate analysis were entered into the multiple logistic regression
models. Independent variables included in both models were age,
sex, whether the participant was employed, income, education,
time to get to clinic, whether the participant drank alcohol, the
main reason for joining the trial, whether the participant received
ART, CD4
+ T-lymphocyte cell count at enrolment, whether the
Table 1. Pharmacy refill rates and urine testing for isoniazid metabolites among participants of the Botswana Isoniazid Preventive
Therapy Trial, 2004–2008.
Period after
enrolment (months)
Participants enrolled at
beginning of period
Attending $80%
of clinic visits
% with detectable urine
isoniazid metabolites in
36H arm*
6H 36H Total
1–6 1995 86% 85% 85% -
7–12 1945 87% 80% 84% -
13–18 1870 79% 77% 78% 80%
{
19–24 1808 79% 76% 77% 79%
{
25–30 1755 79% 75% 77% 74%
1
31–36 1712 79% 77% 78% -
1–36 1995 78% 77% 78% N/A
*Unannounced, urine samples were collected in 2006, 2007 and 2008 from 200 randomly selected participants receiving isoniazid who returned for refills. The numbers
of participants and their median (range) month in the study were:194 at month 13
{ (5–22), 202 at month 22
{ (12–30), 195 at month 30
1 (21–36). Abbreviations: 6H=six
months of isoniazid daily followed by placebo; 36H=36 months of isoniazid daily.
doi:10.1371/journal.pone.0018435.t001
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had difficulties with the regimen, whether the participant believed
isoniazid was dangerous to her/his health, and whether the
participant believed that more information would have helped
her/him remain adherent. ART use and baseline CD4
+ cell count
data were taken from the main clinical trial database and used as
independent variables. In both models adjusted odds ratios
(AORs), 95% confidence intervals (95%CI) and a test for the
overall significance of the model variables with more than 2 levels
(Type 3 analysis of effects test) were computed to assess pairwise
comparisons. Data for visit attendance for pharmacy refills were
also taken from the main clinical trial database and used for
descriptive purposes.
Results
Between November 2004 and July 2006, 1995 participants were
enrolled in the clinical trial. Overall, the clinical trial had a very
good adherence rate during the 3 years of follow-up with 78% of
participants adherent to at least 80% of their scheduled visits, more
than three-quarters of randomly selected participants having
detectable isoniazid metabolites in their urine (Table 1) and 91%
having reached a known study endpoint by 36 months of follow-up.
Sub-study
From the dataset of October 8, 2008, we identified 247 cases
and from a pool of 1370 controls, we randomly selected 253
controls (Fig. 1). At the time of this selection there had been 4,740
person-years of observation which is approximately two-and-a-half
years of follow-up per participant. The median number of days
since the last visit of those cases who were lost to follow-up was 396
days (range 91–1196), and 48 days (range 6–116) for the cases who
were non-adherent.
Phase 1-Group Discussions/Interviews
Cases discussed their views on several topics related to adherence
to the study regimen. There were five in-person group discussions
consisting of 18 individuals (11 females, 7 males) and seven
individualinterviews(3females, 4 males;one face-to-faceandsix via
telephone)fora totalof25individuals.Regardingtheirtreatmentby
clinic staff, cases strongly expressed that the clinical trial staff
provided them with information about their health, treated them
with respect, and imbued them with a sense of empowerment.
Themes associated with barriers to trial participation included, for
example, competing commitments, side effects, and relocation
(Table 2). Cases also provided suggestions as to how to improve
retention in the trial, for example having more dispersed clinics and
communicating requirements related to the trial to the broader
community. Other suggestions are presented in Table 3.
Phase 2-Survey
Among the 500 cases and controls selected for this survey study,
462 completed the survey for a response rate of 92.4% (462/500).
The response rate for the controls (252/253 or 99.6%) was higher
than for the non-adherent (127/145 or 87.6%) and lost to follow-
up cases (83/102 or 81.4%) (Fig. 1). Due to work or personal
Table 2. Examples of group discussion and interview quotations from trial participants who were non-adherent to study
medication or lost to follow-up in the Botswana Isoniazid Preventive Therapy Trial, 2004–2008.
Domain of Inquiry Theme Examples
Reasons joined trial Benefit to self ‘‘It seemed better to prevent than to contract TB.’’
Benefit to others ‘‘…by becoming a participant I could be able to advise other young people and discuss issues like
the importance of programs like IPT with them.’’
Referred ‘‘…I tested positive. And they referred me to the IPT office where I started taking the treatment.’’
Knowledge of TB Symptoms ‘‘It is a cough that is easily spread to other people and you lose a lot of weight.’’
Transmission ‘‘…if you spit on the ground, it can spread to others easily.’’
Facilitators to trial participation Health-related ‘‘I managed to prevent TB and I’m happy because I do not have TB. I know my status. They also
check my CD4 count every time I go for monthly check ups.’’
Barriers to trial participation Competing commitments ‘‘The reasons were work commitments. My job was a barrier to taking the pill but the medication
treated me well.’’
Side effects I always felt like vomiting and my eyes were always itching because of the pills.’’
Started ART ‘‘I was taking a lot of tablets and I was always thinking I will die…so I decided to stop these ones
(isoniazid).’’
Stigma ‘‘They (Batswana) still discriminate against people on the trial and that discrimination is what
makes people drop out of the trial..’’
Relocate ‘‘My job contract came to an end and I had to relocate to my home village’’
Lack of staff ‘‘…the barriers… the one I can think of is the lack of staff.’’
Transport ‘‘When you are far from the clinic, the transport to the clinic becomes a problem.’’
Inconsistent ‘‘…when I was taking the trial medication then I started with ART I asked whether I should
continue with the isoniazid and they said I could just stop isoniazid as its really not a problem.’’
Treatment by clinic staff Respect ‘‘Every time I did not understand, I asked and they made sure they explained clearly in order for me
to understand better.’’
Empower ‘‘They made me realize that I can move forward. I was able to take ART without being reluctant and
this trial made me build a home for my family because of my confidence.’’
Information ‘‘We learned a lot about TB. We have learned how one can be infected, how it can be treated, how
dangerous it is and many more other things.’’
doi:10.1371/journal.pone.0018435.t002
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survey administered over the phone.
Bivariate analysis-associations with non-adherence and
loss to follow-up
Compared to controls, the case non-adherent group was younger
(t=58.2, P,0.0001), and had a greater proportion of men
(x
2(1)=5.7, P=0.017), persons with higher education (x
2(2)=3.6,
P=0.170), persons who drank alcohol (x
2(1)=4.4, P=0.036),
persons who initiated ART (x
2(1)=1.70, P=0.192), persons who
did not understand what was expected when they joined the trial
(x
2(1)=3.3, P=0.071) and persons who experienced any difficulty
with the regimen (x
2(1)=21.9, P,0.0001). Compared to controls,
the case lost to follow-up group was younger (t=49.7, P=0.0001)
and had a greater proportion of men (x
2(1)=14.4, P,0.0001),
persons with a higher income (x
2(2)=4.2, P=0.120), persons with a
higher education (x
2(2)=11.5, P=0.003), persons who reported a
longer time to get to the clinic (x
2(2)=8.9, P=0.012), persons who
drank alcohol (x
2(1)=6.81, P=0.009), persons who had not
initiated ART (x
2(1)=2.81, P=0.094), persons who did not
understand what was expected when they joined the trial
(x
2(1)=9.38, P=0.002),and persons whoexperienced any difficulty
with the regimen (x
2(1)=5.4, P=0.020).
Multivariable regression analysis-associations with non-
adherence and loss to follow-up
Compared to controls, non-adherent participants had greater odds
of being male (AOR 2.24; 95%CI 1.24–4.04) and having difficulties
with the regimen or not knowing if they had difficulties (AOR 3.40;
95%CI 1.75–6.60), and had lower odds of being older (AOR 0.94 for
each year of age; 95%CI 0.91–0.98) (Table 4). Participants lost to
follow-up had higher odds of being male (AOR 3.08; 95%CI 1.50–
6.33) and having a secondary education (AOR 2.55; 95%CI 1.10–
5.91). However, secondary education was not statistically significant
in the Type 3 analysis of the multivariate model.
Self-reported reasons for stopping the medication
Among cases, 40/210 (19.0%) reported that they stopped the
medication because of work commitments (non-adherent 18.9%,
lost to follow-up 19.3%) and 33/210 (15.7%) said they thought
they had completed the study (non-adherent 17.3%, lost to follow-
up 13.3%) (Table 5). Side effects were noted by a larger proportion
of non-adherent cases than those lost to follow-up (15.8% versus
6.0%) and relocation was noted by a larger proportion of cases lost
to follow-up than those who were non-adherent (18.1% versus
7.9%).
Discussion
Adherence and retention in clinical trials are important issues
because participant non-adherence and loss to follow-up can
compromise study results. Generally speaking, patients are less
adherent to treatment when they feel well, such as when taking
prophylactic treatment, than they are for a symptomatic condition
[14,15]. We report on non-adherence and loss to follow-up in
1,995 HIV-infected adults enrolled in a 3-year prophylaxis trial in
two Botswana cities. Based upon the pharmacy refill criterion for
adherence (i.e.,$80% attendance to study medication refill visits),
despite a prolonged 36-month period of prophylaxis, participants
in our trial had a 78% adherence rate which is similar to the 69–
86% rates reported by other clinical trials that provided 6 months
of IPT [16–18]. Using the urine isoniazid metabolite criterion as
an assessment of adherence, participants in the 36-month
Botswana study had a 74–80% adherence rate which is
comparable to the 45–80% rates reported in two other IPT
clinical trials of shorter duration [16,18]. We conducted a case-
control sub-study in which we interviewed 83 participants who
had been lost to follow-up and 127 participants who were non-
adherent to study medication but still attending visits and
compared their demographics and responses to specific questions
with those of 252 adherent participants. Factors associated with
non-adherence or loss to follow-up included age, male sex and
difficulties with the regimen. Additional information from
participants identified side effects and competing commitments
such as work, relocation, and the belief that they had completed
the study as contributions to non-adherence or loss to follow-up.
In the case-control sub-study, men had twice and thrice the odds
of women to be non-adherent or lost to follow-up, respectively.
While we were unable to identify published studies examining
Table 3. Suggestions to improve retention from participants who were non-adherent or lost to follow-up in the Botswana
Isoniazid Preventive Therapy Trial, 2004–2008.
Suggestions
More dispersed clinics
‘‘We need to have a number of dispersed clinics so that people who are residing in rural areas get the medical services they need at the right times.’’
‘‘They should increase study sites because some live far away from towns so that they become nearer to us and we don’t become lazy to visit.’’
Communication of trial requirements to broader community
‘‘Even the bosses should be told about this program so that tomorrow when people ask for permission for these visits every month, they should know what is going on.’’
More staff
‘‘The staff should be increased so that the patients may be assisted quickly.’’
Convenient times for appointments
‘‘They (future participants) should be able to agree on a time that would also be suitable for them.’’
‘‘My request is that some health care workers in this trial should work on weekends.’’
Communication
‘‘You should communicate with us by taking our phone numbers to check how we are doing.’’
Shorter trial
‘‘Three years is also too long, some people may get tired or hopeless and stop taking the medication’’
doi:10.1371/journal.pone.0018435.t003
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HIV-infected adults enrolled in the Botswana Isoniazid Preventive Therapy Trial, 2004–2008.
Demographic Characteristic or Risk Factor Adherent Non-adherent Lost to follow-up
N( % )
1 AOR (95% CI) N (%)
1 AOR (95% CI)
Age (years) Mean6SD 37610 3467 0.94 (0.91, 0.98)* 3566 0.99 (0.95, 1.04)
Sex
Female 199 (79) 86 (68) Referent 48 (58) Referent
Male 53 (21) 41 (32) 2.24 (1.24, 4.04)* 35 (42) 3.08 (1.50, 6.33)*
Employed
Yes 161 (64) 80 (63) – 54 (66) –
No 90 (36) 47 (37) – 28 (34) –
Income per month (Pula)
0–900 96 (52) 41 (43) – 30 (41) Referent
901–2000 58 (31) 35 (37) – 23 (32) 1.26 (0.63, 2.52)
.2000 31 (17) 19 (20) – 20 (27) 1.03 (0.42, 2.53)
Education
Primary or less 99 (41) 38 (31) Referent 18 (22) Referent
Secondary 127 (52) 74 (60) 0.97 (0.51, 1.85) 50 (62) 2.55 (1.10, 5.91)
Tertiary 18 (7) 12 (10) 1.05 (0.39, 2.78) 13 (16) 2.72 (0.68, 10.80)
Time to get to clinic (minutes)
,30 73 (29) 33 (26) – 36 (44) Referent
30–60 144 (58) 76 (60) – 32 (39) 0.64 (0.33, 1.24)
.60 32 (13) 18 (14) – 14 (17) 1.61 (0.61, 4.26)
Do you drink/take alcohol?
No 227 (90) 104 (83) Referent 64 (79) Referent
Yes 25 (10) 22 (17) 1.55 (0.76, 3.17) 17 (21) 1.26 (0.51, 3.09)
Main reason for joining the trial
Prevent TB 167 (66) 78 (61) – 53 (64) –
Other{ 85 (34) 49 (39) – 30 (36) –
Started on antiretroviral
therapy (ART)
Yes 133 (53) 76 (60) Referent 35 (42) Referent
No 119 (47) 51 (40) 0.67 (0.41, 1.10) 48 (58) 1.18 (0.63, 2.21)
Baseline CD4
+ T cell count
$200 cells/mm
3 173 (69) 83 (66) – 56 (68) –
,200 cells/mm
3 76 (31) 43 (34) – 26 (32) –
When I enrolled in the trial, I
understood what was expected
of me
Agree 205 (82) 94 (74) Referent 54 (66) Referent
Disagree/Don’t know 45 (18) 33 (26) 1.65 (0.93, 2.90) 28 (34) 1.87 (0.93, 3.75)
I didn’t have any difficulties with
the regimen
Agree 231 (93) 92 (75) Referent 69 (84) Referent
Disagree/Don’t know 18 (7) 30 (25) 3.40 (1.75, 6.60)* 13 (16) 1.46 (0.58, 3.66)
The isoniazid medication may be
dangerous to my health
Agree 48 (21) 26 (23) – 14 (20) –
Disagree/Don’t know 180 (79) 85 (77) – 57 (80) –
More information about TB would
help me stay with the medication
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infected adults in sub-Saharan Africa, adherence to ART has been
assessed in such populations. Among enrollees of ART programs in
Co ˆte d’Ivoire and Kenya, men were more likely than women to be
lost to follow-up [19,20]. In South Africa, based upon pharmacy
records, women were more likely than men (54% vs 49%, P
,0.001) to take $80% of their ART [21], although this
phenomenon is not limited to South Africa [22]. While reasons
for the increased risk of non-adherence in African men attending
public health clinics are poorly understood, employment circum-
stances and frequency and amount of alcohol use are two possible
explanations. The employment rate in men in the Botswana trial
was higher than women (82% vs. 63%), but the type of employment
and the work hours of men may have made adherence more
difficult. Indeed interview and focus group participants noted that
taking time off from work for study visits was often difficult.
Widespread heavy alcohol use has been reported in Botswana
communities, particularly in men (31% vs. 17% in women) [23] and
was paralleled by observations from the IPT trial (data not shown).
Reasons why HIV-infected men are more likely to be non-adherent
need to be identified in future studies and should guide approaches
taken to improve their adherence.
Non-adherent participants had more than three times the odds
of reporting difficulties with the regimen or not knowing if they
had difficulties than controls (rates reported were 25% in non-
adherent cases vs. 7% in controls) and although not significant in
the multivariable model, participants lost to follow-up also had
higher rates (16%) of reporting these difficulties or not knowing.
Some discussion group and interview participants reported that
the study medication made them sick, lose weight, feel dizzy or
tired or made their body ache. It is well established that side-effects
can greatly influence an individual’s willingness to adhere to
therapy [24,25]. Based upon trial records, none of these
individuals suffered adverse effects of the study medication.
However it is possible that they may have had mild but irritating
symptoms which they did not report to the study staff. This may
represent reporting bias in that patients are more likely to self-
report adverse effects of a medication than clinicians are to record
them [26] or it may represent an excuse for stopping the
medication. Younger age was also associated with non-adherent
participants as has been commonly reported in the medical
literature and also for HIV-infected persons [27–29].
Some associations that were significant in bivariate analysis
were not significant in the adjusted analyses but bear mentioning:
Demographic Characteristic or Risk Factor Adherent Non-adherent Lost to follow-up
N( % )
1 AOR (95% CI) N (%)
1 AOR (95% CI)
Agree 219 (89) 114 (91) – 74 (91) –
Disagree/Don’t know 26 (11) 11 (9) – 7 (9) –
Notes. Missing values are not included; AOR=adjusted odds ratio, SD=standard deviation.
*Overall significant, i.e. P,0.05 by Type 3 analysis of effects.
‘–’=Not included in multiple regression model because P-value.0.25 in bivariate analysis.
{Examples of other responses included:‘‘to receive TB education’’, ‘‘receive free medical care’’, ‘‘to prevent TB’’, ‘‘to receive incentives for taking part’’, ‘‘recruited or
advised to do so’’, ‘‘because I am HIV positive’’, ‘‘to help my country’’, ‘‘to help the study succeed.’’
1For the variable Age, this column reflects the mean 6 standard deviation of the mean (SD).
doi:10.1371/journal.pone.0018435.t004
Table 4. Cont.
Table 5. Self-reported reasons non-adherent and loss to follow-up cases stopped taking isoniazid medication in the Botswana
Isoniazid Preventive Therapy Trial.
Reasons Non-adherent N (%) Lost to follow-up N (%)
Work commitment 24 (18.9) 16 (19.3)
Personal doctor told me to stop because of medical problems including side effects of the
study medication
10 (7.9) 6 (7.2)
Side effects of the study medication (but personal doctor did not tell me to stop) 20 (15.8) 5 (6.0)
Stigma associated with being in the trial 3 (2.4) 2 (2.4)
Relocated too far away to keep appointments 10 (7.9) 15 (18.1)
Not enough transport money (does not include relocating) 2 (1.6) 6 (7.2)
Completed the study (though had not) 22 (17.3) 11 (13.3)
Pregnant 3 (2.4) 3 (3.6)
Take too many pills 1 (0.8) 2 (2.4)
Lost/forgot 7 (5.5) 2 (2.4)
Other{ 23 (18.1) 4 (4.8)
No reason provided 2 (1.6) 11 (13.3)
Total 127 (100%) 83 (100%)
{Examples of other responses included:social problems, religious beliefs, boyfriend threw the pills away, sister flushed the pills down the toilet, pills were stolen,
miscommunication, long lines at the clinic, pills increased appetite.
doi:10.1371/journal.pone.0018435.t005
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understanding the requirements of the study. All four factors have
been reported as barriers to adherence [30,22,31,32]. It may be
that these factors were not independently associated with non-
adherent or lost to follow-up participants in our study because of
small numbers, differences in question comprehension, or
confounding with other variables. For instance, alcohol use may
not have been significant in the adjusted analysis because the
question did not ask about the frequency and quantity of alcohol
consumed. Notably, a relatively large proportion of both groups
(17% non-adherents and 13% lost to follow-up) reported stopping
the medication because they believed they had completed the
study. This may indicate that either nursing staff did not
adequately explain study requirements to the participants or that
the participant did not fully comprehend what was being
explained. Alternatively, as posited by nursing staff, some cases
may have used this option as an excuse because all participants
were required to pass a comprehension test before enrollment.
Our study had several potential limitations. First, data were
cross-sectional, so we cannot state that the significant factors led to
a participant becoming non-adherent or lost to follow-up. Second,
responses to survey questions were self-reported which may have
resulted in some bias in answering questions about non-adherence,
although we believe this was minimized since the study was
conducted by an independent contractor and not members of the
clinic staff. Third, the clinical trial staff did not have control over
the independent administration of ART to study participants
during their changing disease course over the 3-year study. As
HIV-infected persons widely regard ART as life-sustaining and as
ART consists of many additional pills and also have significant
adverse effects, they may have complicated adherence to study
medication. Fourth, we did not assess the personalities of the
participants which could have potentially been a factor in their
adherence to study medication. Fifth, because we were unable to
contact 197 participants who had voluntarily withdrawn at the
time the sub-study was begun, the lack of information about them
may have biased our sub-study. Finally, all of the relevant and
important variables may not have been captured in our survey
(e.g., peer or family social support). The strengths of this study are
the inclusion of group discussions and interviews to supplement the
survey data, clear definitions of non-adherence and loss to follow-
up, and the very high survey response rate.
Studies have shown that participant satisfaction with the clinic
staff can contribute to adherence [32]. In our study, discussion
group and interview participants overwhelmingly praised their
treatment from the clinic staff in a number of areas. Moreover, the
majority of cases responding to the survey agreed that they were
treated well by the clinic staff to the degree that the variables could
not be included in the multiple regression model because the
number of negative responses was too small. Suggestions from the
discussion group and interview participants as to what would
improve their experience ranged from adding weekend clinic
hours to adding more clinics in different locations, but none
related to the way they were treated by clinic staff. For future
clinical trials, potential interventions that might improve adher-
ence in trial participants, even for non-modifiable factors like sex,
include targeting health education for men, reducing barriers (e.g.
offering more clinics in different locations if possible and weekend
hours, making visits brief and convenient), clarifying study
expectations, educating employers about HIV/AIDS to help
reduce stigma in the workplace, and encouraging employers to
support employee health.
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